Use access key #2 to skip to page content.
$3.25 0.01 (0.31%)
8/29/2008 4:00 PM

MannKind Corp (MNKD)

CAPS Rating:
**

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

View All Commentary (MNKD)

Recs

1

Avatar KahanaBob (74.20) Submitted: 6/20/07 4:24 PM : Outperform Start Price: $13.00 MNKD Score: -60.25

I am riding Bill Miller's coatails on this one based on his recommendation in the July Kiplinger article. There is a billion $ market if the inhalers are approved by FDA, and CEO Alfred Mann, is confident enough to have bought 5% of the outstanding shares in the last 3 months. If the product is approved the stock will go to $50 in 3 years. If not, I will write off the loss.

Report this Post Replies: 0 | Reply

Featured Broker Partners